Evaluation of serum and urine biomarkers for severe COVID-19
IntroductionThe new coronavirus disease, COVID-19, poses complex challenges exacerbated by several factors, with respiratory tissue lesions being notably significant among them. Consequently, there is a pressing need to identify informative biological markers that can indicate the severity of the di...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1357659/full |
| _version_ | 1797272532393394176 |
|---|---|
| author | Yaroslav D. Shansky Oleg O. Yanushevich Alina V. Gospodarik Igor V. Maev Natella I. Krikheli Oleg V. Levchenko Andrew V. Zaborovsky Vladimir V. Evdokimov Alexander A. Solodov Petr A. Bely Dmitry N. Andreev Anna N. Serkina Sulejman S. Esiev Sulejman S. Esiev Anastacia V. Komarova Anastacia V. Komarova Philip S. Sokolov Aleksei K. Fomenko Mikhail K. Devkota Sergei V. Tsaregorodtsev Julia A. Bespyatykh Julia A. Bespyatykh |
| author_facet | Yaroslav D. Shansky Oleg O. Yanushevich Alina V. Gospodarik Igor V. Maev Natella I. Krikheli Oleg V. Levchenko Andrew V. Zaborovsky Vladimir V. Evdokimov Alexander A. Solodov Petr A. Bely Dmitry N. Andreev Anna N. Serkina Sulejman S. Esiev Sulejman S. Esiev Anastacia V. Komarova Anastacia V. Komarova Philip S. Sokolov Aleksei K. Fomenko Mikhail K. Devkota Sergei V. Tsaregorodtsev Julia A. Bespyatykh Julia A. Bespyatykh |
| author_sort | Yaroslav D. Shansky |
| collection | DOAJ |
| description | IntroductionThe new coronavirus disease, COVID-19, poses complex challenges exacerbated by several factors, with respiratory tissue lesions being notably significant among them. Consequently, there is a pressing need to identify informative biological markers that can indicate the severity of the disease. Several studies have highlighted the involvement of proteins such as APOA1, XPNPEP2, ORP150, CUBN, HCII, and CREB3L3 in these respiratory tissue lesions. However, there is a lack of information regarding antibodies to these proteins in the human body, which could potentially serve as valuable diagnostic markers for COVID-19. Simultaneously, it is relevant to select biological fluids that can be obtained without invasive procedures. Urine is one such fluid, but its effect on clinical laboratory analysis is not yet fully understood due to lack of study on its composition.MethodsMethods used in this study are as follows: total serum protein analysis; ELISA on moderate and severe COVID-19 patients’ serum and urine; bioinformatic methods: ROC analysis, PCA, SVM.Results and discussionThe levels of antiAPOA1, antiXPNPEP2, antiORP150, antiCUBN, antiHCII, and antiCREB3L3 exhibit gradual fluctuations ranging from moderate to severe in both the serum and urine of COVID-19 patients. However, the diagnostic value of individual anti-protein antibodies is low, in both blood serum and urine. On the contrary, joint detection of these antibodies in patients’ serum significantly increases the diagnostic value as demonstrated by the results of principal component analysis (PCA) and support vector machine (SVM). The non-linear regression model achieved an accuracy of 0.833. Furthermore, PCA aided in identifying serum protein markers that have the greatest impact on patient group discrimination. The study revealed that serum serves as a superior analyte for describing protein quantification due to its consistent composition and lack of organic salts and drug residues, which can otherwise affect protein stability. |
| first_indexed | 2024-03-07T14:30:43Z |
| format | Article |
| id | doaj.art-14ea6d7aa10142cc8d6accaaf659d7e2 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-07T14:30:43Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-14ea6d7aa10142cc8d6accaaf659d7e22024-03-06T05:03:33ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-03-011110.3389/fmed.2024.13576591357659Evaluation of serum and urine biomarkers for severe COVID-19Yaroslav D. Shansky0Oleg O. Yanushevich1Alina V. Gospodarik2Igor V. Maev3Natella I. Krikheli4Oleg V. Levchenko5Andrew V. Zaborovsky6Vladimir V. Evdokimov7Alexander A. Solodov8Petr A. Bely9Dmitry N. Andreev10Anna N. Serkina11Sulejman S. Esiev12Sulejman S. Esiev13Anastacia V. Komarova14Anastacia V. Komarova15Philip S. Sokolov16Aleksei K. Fomenko17Mikhail K. Devkota18Sergei V. Tsaregorodtsev19Julia A. Bespyatykh20Julia A. Bespyatykh21Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaLaboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaLaboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaLaboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaDepartment of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, RussiaLaboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaDepartment of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, RussiaLaboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, RussiaDepartment of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, RussiaIntroductionThe new coronavirus disease, COVID-19, poses complex challenges exacerbated by several factors, with respiratory tissue lesions being notably significant among them. Consequently, there is a pressing need to identify informative biological markers that can indicate the severity of the disease. Several studies have highlighted the involvement of proteins such as APOA1, XPNPEP2, ORP150, CUBN, HCII, and CREB3L3 in these respiratory tissue lesions. However, there is a lack of information regarding antibodies to these proteins in the human body, which could potentially serve as valuable diagnostic markers for COVID-19. Simultaneously, it is relevant to select biological fluids that can be obtained without invasive procedures. Urine is one such fluid, but its effect on clinical laboratory analysis is not yet fully understood due to lack of study on its composition.MethodsMethods used in this study are as follows: total serum protein analysis; ELISA on moderate and severe COVID-19 patients’ serum and urine; bioinformatic methods: ROC analysis, PCA, SVM.Results and discussionThe levels of antiAPOA1, antiXPNPEP2, antiORP150, antiCUBN, antiHCII, and antiCREB3L3 exhibit gradual fluctuations ranging from moderate to severe in both the serum and urine of COVID-19 patients. However, the diagnostic value of individual anti-protein antibodies is low, in both blood serum and urine. On the contrary, joint detection of these antibodies in patients’ serum significantly increases the diagnostic value as demonstrated by the results of principal component analysis (PCA) and support vector machine (SVM). The non-linear regression model achieved an accuracy of 0.833. Furthermore, PCA aided in identifying serum protein markers that have the greatest impact on patient group discrimination. The study revealed that serum serves as a superior analyte for describing protein quantification due to its consistent composition and lack of organic salts and drug residues, which can otherwise affect protein stability.https://www.frontiersin.org/articles/10.3389/fmed.2024.1357659/fullCOVID-19serological testscubilinXPNPEP2 proteinORP150 proteinapolipoprotein A-I |
| spellingShingle | Yaroslav D. Shansky Oleg O. Yanushevich Alina V. Gospodarik Igor V. Maev Natella I. Krikheli Oleg V. Levchenko Andrew V. Zaborovsky Vladimir V. Evdokimov Alexander A. Solodov Petr A. Bely Dmitry N. Andreev Anna N. Serkina Sulejman S. Esiev Sulejman S. Esiev Anastacia V. Komarova Anastacia V. Komarova Philip S. Sokolov Aleksei K. Fomenko Mikhail K. Devkota Sergei V. Tsaregorodtsev Julia A. Bespyatykh Julia A. Bespyatykh Evaluation of serum and urine biomarkers for severe COVID-19 Frontiers in Medicine COVID-19 serological tests cubilin XPNPEP2 protein ORP150 protein apolipoprotein A-I |
| title | Evaluation of serum and urine biomarkers for severe COVID-19 |
| title_full | Evaluation of serum and urine biomarkers for severe COVID-19 |
| title_fullStr | Evaluation of serum and urine biomarkers for severe COVID-19 |
| title_full_unstemmed | Evaluation of serum and urine biomarkers for severe COVID-19 |
| title_short | Evaluation of serum and urine biomarkers for severe COVID-19 |
| title_sort | evaluation of serum and urine biomarkers for severe covid 19 |
| topic | COVID-19 serological tests cubilin XPNPEP2 protein ORP150 protein apolipoprotein A-I |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1357659/full |
| work_keys_str_mv | AT yaroslavdshansky evaluationofserumandurinebiomarkersforseverecovid19 AT olegoyanushevich evaluationofserumandurinebiomarkersforseverecovid19 AT alinavgospodarik evaluationofserumandurinebiomarkersforseverecovid19 AT igorvmaev evaluationofserumandurinebiomarkersforseverecovid19 AT natellaikrikheli evaluationofserumandurinebiomarkersforseverecovid19 AT olegvlevchenko evaluationofserumandurinebiomarkersforseverecovid19 AT andrewvzaborovsky evaluationofserumandurinebiomarkersforseverecovid19 AT vladimirvevdokimov evaluationofserumandurinebiomarkersforseverecovid19 AT alexanderasolodov evaluationofserumandurinebiomarkersforseverecovid19 AT petrabely evaluationofserumandurinebiomarkersforseverecovid19 AT dmitrynandreev evaluationofserumandurinebiomarkersforseverecovid19 AT annanserkina evaluationofserumandurinebiomarkersforseverecovid19 AT sulejmansesiev evaluationofserumandurinebiomarkersforseverecovid19 AT sulejmansesiev evaluationofserumandurinebiomarkersforseverecovid19 AT anastaciavkomarova evaluationofserumandurinebiomarkersforseverecovid19 AT anastaciavkomarova evaluationofserumandurinebiomarkersforseverecovid19 AT philipssokolov evaluationofserumandurinebiomarkersforseverecovid19 AT alekseikfomenko evaluationofserumandurinebiomarkersforseverecovid19 AT mikhailkdevkota evaluationofserumandurinebiomarkersforseverecovid19 AT sergeivtsaregorodtsev evaluationofserumandurinebiomarkersforseverecovid19 AT juliaabespyatykh evaluationofserumandurinebiomarkersforseverecovid19 AT juliaabespyatykh evaluationofserumandurinebiomarkersforseverecovid19 |